Eli Lilly and Company (NYSE:LLY) Upgraded by Erste Group Bank to Buy

Erste Group Bank upgraded shares of Eli Lilly and Company (NYSE:LLYFree Report) from a hold rating to a buy rating in a report issued on Wednesday, Benzinga reports.

Several other research firms have also commented on LLY. TheStreet upgraded shares of Eli Lilly and Company from a c+ rating to a b rating in a report on Friday, March 8th. Cantor Fitzgerald reissued an overweight rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research report on Monday. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a buy rating in a research report on Tuesday. Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a buy rating in a report on Friday, March 1st. Finally, Barclays raised their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an overweight rating in a report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of Moderate Buy and an average target price of $700.00.

Get Our Latest Stock Report on LLY

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $776.31 on Wednesday. The company has a market capitalization of $737.62 billion, a P/E ratio of 133.85, a P/E/G ratio of 1.67 and a beta of 0.34. The company’s 50-day simple moving average is $742.32 and its two-hundred day simple moving average is $642.33. Eli Lilly and Company has a one year low of $351.27 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period last year, the business posted $2.09 EPS. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, equities analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 12,344 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $634.13, for a total value of $7,827,700.72. Following the completion of the transaction, the insider now owns 99,543,810 shares of the company’s stock, valued at approximately $63,123,716,235.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 180,667 shares of company stock valued at $116,186,189. 0.13% of the stock is owned by insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently made changes to their positions in LLY. Versant Capital Management Inc increased its holdings in Eli Lilly and Company by 1.8% in the first quarter. Versant Capital Management Inc now owns 736 shares of the company’s stock valued at $573,000 after buying an additional 13 shares in the last quarter. Waller Financial Planning Group Inc. purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $214,000. Heartwood Wealth Advisors LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth about $223,000. Stonehearth Capital Management LLC purchased a new position in Eli Lilly and Company during the first quarter worth approximately $206,000. Finally, Modus Advisors LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $268,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.